Comparison of the Effect of Compound CDRI 80/53 [N-(3-acetyl-4,5-dihydro-2-furanyl)-N4-(6 -methoxy-8-quinolinyl)1,4- pentanediamine] with Primaquine on Human Erythrocytes In Vitro

dc.contributor.author	Anklesaria, P S
dc.contributor.author	Ashar, V J
dc.contributor.author	Kshirsagar, N A
dc.contributor.author	Gupta, K C
dc.date.accessioned	2009-09-08T08:58:57Z
dc.date.available	2009-09-08T08:58:57Z
dc.date.issued	1994
dc.identifier.citation	Tropical diseases: molecular biology & control strategies,1994,256-261	en
dc.identifier.uri	http://hdl.handle.net/123456789/505
dc.description.abstract	Comparative in vitro study of a malaria antirelapse compound CDRI Code 80/53 with primaquine (PQ) was done on the erythrocytes of eight normal and six G-6-PD-deficient individuals. Reduced glutathione (GSH) was estimated in the RBCs exposed to the in vitro action of the drugs. Statistically significant decreases were observed at 25 ug/ml and 50 µ/ml doses of PQ as compared t the equivalent doses of compound 80/53 in both normal and G-6-PD-deficient erythrocytes. The study showed that compound CDRI 80/53 did not damage normal as well as G-6-PD-deficient erythrocytes to the same extent as PQ.	en
dc.format.extent	1382605 bytes
dc.format.mimetype	application/pdf
dc.language.iso	en	en
dc.title	Comparison of the Effect of Compound CDRI 80/53 [N-(3-acetyl-4,5-dihydro-2-furanyl)-N4-(6 -methoxy-8-quinolinyl)1,4- pentanediamine] with Primaquine on Human Erythrocytes In Vitro	en
dc.type	Book chapter	en